To PET or not to PET? That is the question. Staging in anal cancer.


BACKGROUND Anal cancer is a rare tumour accounting for ∼2% of all colorectal cancers between 1997 and 2000 in the UK. Staging is still dominated by DRE (digital rectal examination), computed tomography (CT) and magnetic resonance imaging (MRI) imaging. The role of PET as a definitive modality is still emerging and there are relatively few adequate studies in the literature. METHODS We looked at patients treated radically for anal cancer at Mount Vernon Cancer Centre (UK) between 2009 and 2010. Eighty-eight patients underwent treatment according to data-based coding records of which 46 had positron emission tomography (PET)/CT scans. Notes were unavailable for three patients. We compared staging following conventional modalities (DRE, MRI and CT) and PET/CT scans for these 43 patients. RESULTS In 18 patients, the PET/CT stage differed from MRI. PET/CT altered the stage in 42% of patients but changes in subsequent management were not implemented. CONCLUSIONS Our data show that PET/CT does alter staging in a significant number of cases although it did not lead to change in management under the current guidelines. Furthermore, there is agreement that PET/CT shows greater sensitivity for detection of lymph nodes and our study has demonstrated a distinct trend towards upstaging of anal cancer with PET/CT.

DOI: 10.1093/annonc/mdr599

2 Figures and Tables

Citations per Year

72 Citations

Semantic Scholar estimates that this publication has 72 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bhuva2012ToPO, title={To PET or not to PET? That is the question. Staging in anal cancer.}, author={Neel J Bhuva and Robert G T Glynne-Jones and L. I. Sonoda and W L Wong and Marion Harrison}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2012}, volume={23 8}, pages={2078-82} }